CCL2 and leukemia: Zhao et al. found that c-Met inhibition increased the secretion of various cytokines, including CCL2, IL8, or leukemia suppressor, and promoted the interaction between these cytokine receptors and Janus kinase 1/2 (JAK1/2), thus activating the JAKs/STAT3 signaling pathway and thus inhibiting the progression of esophageal squamous cell carcinoma [32].